الفهرس 
OVERVIEW OF DIABETIC MACULAR EDEMAOnly 14 pages are availabe for public view
 |  | from | 118 |  |  |
| | | from | 118 | | |
Abstract
Subthreshold micro pulse yellow laser showed long-term
efficacy in diffuse diabetic macular edema treatment in
reducing central macular thickness and improving visual acuity.
The level of HbA1c did not correlate significantly with the
initial and final macular sensitivity, BCVA and CMT. The
SMPLT is safe procedure, because no retinal damage was
observed after laser treatment.
Morphologic and visual function data reported in this
study are adding new insights about safety of yellow MPL
treatments in DME.
Our study evaluated yellow 577-nm micro pulse laser in
patients with DME. There was a statistically significant
improvement in VA at follow-up visits, statistically significant
decrease of the central macular thickness on OCT, and there was
a statistically significant improvement in macular sensitivity at
follow-up visits.
Our study is one of a few studies to evaluate
modifications on OCTA, after SMPL treatment in DME,
documenting more pronounced changes in the DCP than in the
SCP (decrease in FAZ area, number of MA). A significant
decrease in the number of MA in the SCP and DCP occurred as
early as 3 months after SMPL.
The safety and efficacy profiles of sub threshold micro
pulse laser are especially important in the era of intravitreal
treatment for DME. In fact, in eyes with mild center-involving
DME, or center non involving DME, and with preserved visual
acuity. It is essential to avoid morphologic and visual function
macular damage, as it always happens with ETDRS laser.
Moreover, the use of intravitreal treatment in these
patients might not be justified by its potential local and
systemic complications. On the other side, the rationale to wait
without treatment or lately treated may have a permanent loss
of visual acuity or retinal sensitivity. Therefore, the use of non
invasive and safe laser treatments may be the most suitable
option in specific cases.
Therapy using 577-nm laser treatment has several
advantages. The cost of 577-nm laser is lower when compared
to that of anti-VEGF drugs. Moreover, unlike the traditional
532-nm laser, a yellow wavelength can be repeatedly
performed on a macular area. Many patients in the clinic
refused to receive anti-VEGF treatment when they knew the
high cost. We should at least recommend a laser treatment for
them, especially for the ones with low compliance.